# Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

> **NCT07365410** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Brain Metastases
- Furmonertinib
- EGFR Mutation

## Interventions

- **DRUG:** Furmonertinib
- **DRUG:** Furmonertinib
- **DRUG:** carboplatin
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT07365410
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2026-05
- **Final completion:** 2028-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07365410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07365410, "Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07365410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*